YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided earnings guidance for the six months ended June 30, 2023. For the period, the group expected to record a turnover of approximately RMB 3.2 billion for the six months ended 30 June 2023, representing an increase of approximately 147% as compared to the turnover of approximately RMB 1.293 billion recorded for the six months ended 30 June 2022. The Group is expected to record a net profit attributable to the parent company of approximately RMB1 billion to approximately RMB 1.2 billion for the six months ended 30 June 2023, representing an increase of approximately RMB 1.033 billion to approximately RMB 1.233 billion as compared to a net loss attributable to the parent company of approximately RMB 33 million for the six months ended 30 June 2022.

The expected increase is mainly due to the overall lifting of domestic epidemic prevention and control policies, the gradual improvement of social and economic performance, the footfall and daily social activities have gradually resumed to normal, and the traffic, diagnosis activities and the volume of prescriptions in frontline medical facilities have shown encouraging signs of recovery, and the good performance of the Group's business pipelines.